Inflammation, atherosclerosis, and coronary artery disease: PET/CT for the evaluation of atherosclerosis and inflammation

Clinical Medicine Insights: Cardiology

Volumn 8, Issue Suppl. 3, 2014, Pages 13-21

  Alie, Nadia ^a   Eldib, Mootaz ^a   Fayad, Zahi A ^a   Mani, Venkatesh ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

18 F FDG; Atherosclerosis; Computed tomography; Inflammation; Plaque; Positron emission tomography

Indexed keywords

CHOLINE C 11; FLUORODEOXYGLUCOSE F 18; FLUOROMETHYLCHOLINE F 18; GALLIUM DOTATATE GA 68; RADIOPHARMACEUTICAL AGENT; SODIUM FLUORIDE F 18; UNCLASSIFIED DRUG;

ARTERY CALCIFICATION; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORONARY ARTERY DISEASE; GENE EXPRESSION; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; INTERMETHOD COMPARISON; IONIZING RADIATION; MACROPHAGE; METABOLIC SYNDROME X; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRECLINICAL STUDY; RADIOACTIVITY; REVIEW; SIGNAL PROCESSING; VASCULITIS;

EID: 84981722711     PISSN: None     EISSN: 11795468     Source Type: Journal    
DOI: 10.4137/CMC.S17063     Document Type: Review

References (105)

1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–43.
2. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2002;32(9):2045–51.
3. Fruchart JC, Nierman MC, Stroes ES, Kastelein JJ, Duriez P. New risk factors for atherosclerosis and patient risk assessment. Circulation. 2004;109(23 suppl 1):III15–9.
4. Robbins CS, Hilgendorf I, Weber GF, et al. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med. 2013;19(9):1166–72.
5. Vita JA. Endothelial function. Circulation. 2014;124(25):e906–12.
6. Vita JA, Keaney JF Jr, Larson MG, et al. Brachial artery vasodilator function and systemic inflammation in the Framingham offspring study. Circulation. 2004;110(23):3604–9.
7. Baldassarre D, Veglia F, Hamsten A, et al; IMPROVE Study Group. Progression of carotid intima-media thickness as predictor of vascular events: results from the IMPROVE study. Arterioscler Thromb Vasc Biol. 2013;33(9):2273–9.
8. Gepner AD, Korcarz CE, Colangelo LA, et al. Longitudinal effects of a decade of aging on carotid artery stiffness: the multiethnic study of atherosclerosis. Stroke. 2014;45(1):48–53.
9. Jickling GC, Chaturvedi S. Carotid plaque inflammation in stroke assessed by PET: a burning issue? Neurology. 2014;82(19):1672–3.
10. Davies MJ, Thomas AC. Plaque fissuring – the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J. 1985;53(4):363–73.
11. Shalhoub J, Oskrochi Y, Davies AH, Owen DR. Clinical assessment of carotid atherosclerosis inflammation by positron emission tomography. Curr Mol Med. 2013;13(10):1646–52.
12. Osborn EA, Jaffer FA. The advancing clinical impact of molecular imaging in CVD. JACC Cardiovasc Imaging. 1327;6(12):1327–41.
13. Quillard T, Libby P. Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development. Circ Res. 2012;111(2):231–44.
14. Rudd JH, Hyafil F, Fayad ZA. Inflammation imaging in atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29(7):1009–16.
15. Townsend DW, Cherry SR. Combining anatomy and function: the path to true image fusion. Eur Radiol. 2001;11(10):1968–74.
16. Dweck MR, Chow MW, Joshi NV, et al. Coronary arterial 18F-sodium fluoride uptake: a novel marker of plaque biology. J Am Coll Cardiol. 2012;59(17):1539–48.
17. Menezes LJ, Kayani I, Ben-Haim S, Hutton B, Ell PJ, Groves AM. What is the natural history of 18F-FDG uptake in arterial atheroma on PET/CT? Implications for imaging the vulnerable plaque. Atherosclerosis. 2010;211(1):136–40.
18. Myers KS, Rudd JH, Hailman EP, et al. Correlation between arterial FDG uptake and biomarkers in peripheral artery disease. JACC Cardiovasc Imaging. 2012;5(1):38–45.
19. Kang S, Kyung C, Park JS, et al. Subclinical vascular inflammation in subjects with normal weight obesity and its association with body fat: an 18 F-FDG-PET/CT study. Cardiovasc Diabetol. 2014;13:70.
20. Golia E, Limongelli G, Natale F, et al. Inflammation and cardiovascular disease: from pathogenesis to therapeutic target. Curr Atheroscler Rep. 1007;16(9):435.
21. Wong BW, Meredith A, Lin D, McManus BM. The biological role of inflammation in atherosclerosis. Can J Cardiol. 2012;28(6):631–41.
22. Elkhawad M, Rudd JH. Radiotracer imaging of atherosclerotic plaque biology. Cardiol Clin. 2009;27(2):345–54.
23. Graebe M, Pedersen SF, Borgwardt L, Hojgaard L, Sillesen H, Kjaer A. Molecular pathology in vulnerable carotid plaques: correlation with [18]-fluorodeoxyglucose positron emission tomography (FDG-PET). Eur J Vasc Endovasc Surg. 2009;37(6):714–21.
24. Lairez O, Fayad ZA. Imaging of atherosclerosis: can molecular imaging do more? Arch Cardiovasc Dis. 2013;106(11):551–3.
25. Rudd JH, Myers KS, Bansilal S, et al. Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging. 2009;2(2):107–15.
26. Jaff MR, Goldmakher GV, Lev MH, Romero JM. Imaging of the carotid arteries: the role of duplex ultrasonography, magnetic resonance arteriography, and computerized tomographic arteriography. Vasc Med. 2008;13(4):281–92.
27. Tarkin JM, Joshi FR, Rudd JH. PET imaging of inflammation in atherosclerosis. Nat Rev Cardiol. 1038;2014(10):80.
28. El-Haddad G, Zhuang H, Gupta N, Alavi A. Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders. Semin Nucl Med. 2004;34(4):313–29.
29. Rominger A, Saam T, Wolpers S, et al. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med. 2009;50(10):1611–20.
30. Fowler JS, Ido T. Initial and subsequent approach for the synthesis of 18FDG. Semin Nucl Med. 2002;32(1):6–12.
31. Som P, Atkins HL, Bandoypadhyay D, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-d-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med. 1980;21(7):670–5.
32. Yun M, Yeh D, Araujo LI, Jang S, Newberg A, Alavi A. F-18 FDG uptake in the large arteries: a new observation. Clin Nucl Med. 2001;26(4):314–9.
33. Yun M, Jang S, Cucchiara A, Newberg AB, Alavi A. 18F FDG uptake in the large arteries: a correlation study with the atherogenic risk factors. Semin Nucl Med. 2002;32(1):70–6.
34. Lederman RJ, Raylman RR, Fisher SJ, et al. Detection of atherosclerosis using a novel positron-sensitive probe and 18-fluorodeoxyglucose (FDG). Nucl Med Commun. 2001;22(7):747–53.
35. Ben-Haim S, Kupzov E, Tamir A, Israel O. Evaluation of 18F-FDG uptake and arterial wall calcifications using 18F-FDG PET/CT. J Nucl Med. 2004;45(11):1816–21.
36. Ben-Haim S, Kupzov E, Tamir A, Frenkel A, Israel O. Changing patterns of abnormal vascular wall F-18 fluorodeoxyglucose uptake on follow-up PET/CT studies. J Nucl Cardiol. 2006;13(6):791–800.
37. Weisdorf DJ, Craddock PR, Jacob HS. Granulocytes utilize different energy sources for movement and phagocytosis. Inflammation. 1982;6(3):245–56.
38. Sluimer JC, Daemen MJ. Novel concepts in atherogenesis: angiogenesis and hypoxia in atherosclerosis. J Pathol. 2009;218(1):7–29.
39. Chiong M, Morales P, Torres G, et al. Influence of glucose metabolism on vascular smooth muscle cell proliferation. Vasa. 1024;42(1):8–16.
40. Newsholme P, Curi R, Gordon S, Newsholme EA. Metabolism of glucose, glutamine, long-chain fatty acids and ketone bodies by murine macrophages. Biochem J. 1986;239(1):121–5.
41. Garedew A, Henderson SO, Moncada S. Activated macrophages utilize glycolytic ATP to maintain mitochondrial membrane potential and prevent apoptotic cell death. Cell Death Differ. 2010;17(10):1540–50.
42. Newsholme P, Gordon S, Newsholme EA. Rates of utilization and fates of glucose, glutamine, pyruvate, fatty acids and ketone bodies by mouse macrophages. Biochem J. 1987;242(3):631–6.
43. Fu Y, Maianu L, Melbert BR, Garvey WT. Facilitative glucose transporter gene expression in human lymphocytes, monocytes, and macrophages: a role for GLUT isoforms 1, 3, and 5 in the immune response and foam cell formation. Blood Cells Mol Dis. 2004;32(1):182–90.
44. Pedersen SF, Graebe M, Fisker Hag AM, Hojgaard L, Sillesen H, Kjaer A. Gene expression and 18FDG uptake in atherosclerotic carotid plaques. Nucl Med Commun. 2010;31(5):423–9.
45. Tavakoli S, Zamora D, Ullevig S, Asmis R. Bioenergetic profiles diverge during macrophage polarization: implications for the interpretation of 18F-FDG PET imaging of atherosclerosis. J Nucl Med. 1661;54(9):1661–7.
46. Tawakol A, Migrino RQ, Bashian GG, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006;48(9):1818–24.
47. Hiari N, Rudd JH. FDG PET imaging and cardiovascular inflammation. Curr Cardiol Rep. 2011;13(1):43–8.
48. Font MA, Fernandez A, Carvajal A, et al. Imaging of early inflammation in low-to-moderate carotid stenosis by 18-FDG-PET. Front Biosci (Landmark Ed). 2009;14:3352–60.
49. Tawakol A, Migrino RQ, Hoffmann U, et al. Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography. J Nucl Cardiol. 2005;12(3):294–301.
50. Rudd JH, Myers KS, Bansilal S, et al. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nuc Med. 2008;49(6):871–8.
51. Bucerius J, Mani V, Moncrieff C, et al. Optimizing 18F-FDG PET/CT imaging of vessel wall inflammation: the impact of 18F-FDG circulation time, injected dose, uptake parameters, and fasting blood glucose levels. Eur J Nucl Med Mol Imaging. 2014;41(2):369–83.
52. Oh M, Kim JY, Shin KH, et al. Imaging atherosclerosis in the carotid arteries with F-18-Fluoro-2-deoxy-d-glucose positron emission tomography: effect of imaging time after injection on quantitative measurement. Nucl Med Mol Imaging. 2010;44(4):261–6.
53. Hyafil F, Cornily JC, Rudd JH, Machac J, Feldman LJ, Fayad ZA. Quantification of inflammation within rabbit atherosclerotic plaques using the macrophage-specific CT contrast agent N1177: a comparison with 18F-FDG PET/CT and histology. J Nucl Med. 2009;50(6):959–65.
54. Ishino S, Ogawa M, Mori I, et al. 18F-FDG PET and intravascular ultrasonography (IVUS) images compared with histology of atherosclerotic plaques: 18F-FDG accumulates in foamy macrophages. Eur J Nucl Med Mol Imaging. 2014;41(4):624–33.
55. Zhao QM, Feng TT, Zhao X, et al. Imaging of atherosclerotic aorta of rabbit model by detection of plaque inflammation with fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography. Chin Med J (Engl). 2011;124(6):911–7.
56. Riou LM, Broisat A, Dimastromatteo J, Pons G, Fagret D, Ghezzi C. Pre-clinical and clinical evaluation of nuclear tracers for the molecular imaging of vulnerable atherosclerosis: an overview. Curr Med Chem. 2009;16(12):1499–511.
57. Ogawa M, Nakamura S, Saito Y, Kosugi M, Magata Y. What can be seen by 18F-FDG PET in atherosclerosis imaging? The effect of foam cell formation on 18F-FDG uptake to macrophages in vitro. J Nucl Med. 2012;53(1):55–8.
58. Hag AM, Pedersen SF, Christoffersen C, et al. (18)F-FDG PET imaging of murine atherosclerosis: association with gene expression of key molecular markers. PLoS One. 2012;7(11):e50908.
59. Wenning C, Kloth C, Kuhlmann MT, et al. Serial F-18-FDG PET/CT distinguishes inflamed from stable plaque phenotypes in shear-stress induced murine atherosclerosis. Atherosclerosis. 2014;234(2):276–82.
60. Laurberg JM, Olsen AK, Hansen SB, et al. Imaging of vulnerable atherosclerotic plaques with FDG-microPET: no FDG accumulation. Atherosclerosis. 2007;192(2):275–82.
61. -/-mice. PLoS One. 2014;9(7):e99441.
62. Millon A, Dickson SD, Klink A, et al. Monitoring plaque inflammation in atherosclerotic rabbits with an iron oxide (P904) and (18)F-FDG using a combined PET/MR scanner. Atherosclerosis. 2013;228(2):339–45.
63. Zhao QM, Zhao X, Feng TT, et al. Detection of vulnerable atherosclerotic plaque and prediction of thrombosis events in a rabbit model using 18F-FDG -PET/CT. PLoS One. 2013;8(4):e61140.
64. Calcagno C, Cornily JC, Hyafil F, et al. Detection of neovessels in atherosclerotic plaques of rabbits using dynamic contrast enhanced MRI and 18F-FDG PET. Arterioscler Thromb Vasc Biol. 2008;28(7):1311–7.
65. Orbay H, Hong H, Zhang Y, Cai W. Positron emission tomography imaging of atherosclerosis. Theranostics. 2013;3(11):894–902.
66. Rudd JH, Warburton EA, Fryer TD, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002;105(23):2708–11.
67. Kim TN, Kim S, Yang SJ, et al. Vascular inflammation in patients with impaired glucose tolerance and type 2 diabetes: analysis with 18F-fluorodeoxyglucose positron emission tomography. Circ Cardiovasc Imaging. 2010;3(2):142–8.
68. Tahara N, Kai H, Yamagishi S, et al. Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol. 2007;49(14):1533–9.
69. Graebe M, Pedersen SF, Hojgaard L, Kjaer A, Sillesen H. 18FDG PET and ultrasound echolucency in carotid artery plaques. JACC Cardiovasc Imaging. 2010;3(3):289–95.
70. Khalil A, Orellana MR, Fulop T, Turcotte EE, Bentourkia M. Positron emission tomography imaging for vascular inflammation evaluation in elderly subjects with different risk factors for cardiovascular diseases. Am J Nucl Med Mol Imaging. 2014;4(3):283–92.
71. Wu YW, Kao HL, Chen MF, et al. Characterization of plaques using 18F-FDG PET/CT in patients with carotid atherosclerosis and correlation with matrix metalloproteinase−1. J Nucl Med. 2007;48(2):227–33.
72. Noh TS, Moon SH, Cho YS, et al. Relation of carotid artery 18F-FDG uptake to C-reactive protein and Framingham risk score in a large cohort of asymptomatic adults. J Nucl Med. 2013;54(12):2070–6.
73. Montagnana M, Danese E, Lippi G. Genetic risk factors of atherothrombosis. Pol Arch Med Wewn. 2014;124(9):474–82.
74. Basu S, Zhuang H, Alavi A. Imaging of lower extremity artery atherosclerosis in diabetic foot: FDG-PET imaging and histopathological correlates. Clin Nucl Med. 2007;32(7):567–8.
75. Mehta NN, Torigian DA, Gelfand JM, Saboury B, Alavi A. Quantification of atherosclerotic plaque activity and vascular inflammation using [18-F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). J Vis Exp. 2012;2(63):e3777.
76. Rogers IS, Nasir K, Figueroa AL, et al. Feasibility of FDG imaging of the coronary arteries: comparison between acute coronary syndrome and stable angina. JACC Cardiovasc Imaging. 2010;3(4):388–97.
77. Strobl FF, Rominger A, Wolpers S, et al. Impact of cardiovascular risk factors on vessel wall inflammation and calcified plaque burden differs across vascular beds: a PET-CT study. Int J Cardiovasc Imaging. 2013;29(8):1899–908.
78. Joshi NV, Vesey AT, Williams MC, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet. 2013;383(9918):705–13.
79. Cheng VY, Slomka PJ, Le Meunier L, et al. Coronary arterial 18F-FDG uptake by fusion of PET and coronary CT angiography at sites of percutaneous stenting for acute myocardial infarction and stable coronary artery disease. J Nucl Med. 2012;53(4):575–83.
80. Varghese A, Crowe LA, Mohiaddin RH, et al. Inter-study reproducibility of 3D volume selective fast spin echo sequence for quantifying carotid artery wall volume in asymptomatic subjects. Atherosclerosis. 2005;183(2):361–6.
81. Rudd JH, Myers KS, Bansilal S, et al. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol. 2007;50(9):892–6.
82. Fox JJ, Strauss HW. One step closer to imaging vulnerable plaque in the coronary arteries. J Nucl Med. 2009;50(4):497–500.
83. Saam T, Rominger A, Wolpers S, et al. Association of inflammation of the left anterior descending coronary artery with cardiovascular risk factors, plaque burden and pericardial fat volume: a PET/CT study. Eur J Nucl Med Mol Imaging. 2010;37(6):1203–12.
84. Williams G, Kolodny GM. Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. AJR Am J Roentgenol. 2008;190(2):W151–6.
85. Williams G, Kolodny GM. Retrospective study of coronary uptake of 18F-fluorodeoxyglucose in association with calcification and coronary artery disease: a preliminary study. Nucl Med Commun. 2009;30(4):287–91.
86. Laitinen IE, Luoto P, Någren K, et al. Uptake of 11C-choline in mouse atherosclerotic plaques. J Nucl Med. 2010;51(5):798–802.
87. Matter CM, Wyss MT, Meier P, et al. 18F-choline images murine atherosclerotic plaques ex vivo. Arterioscler Thromb Vasc Biol. 2006;26(3):584–9.
88. Bucerius J, Schmaljohann J, Böhm I, et al. Feasibility of 18F-fluoromethylcholine PET/CT for imaging of vessel wall alterations in humans – first results. Eur J Nucl Med Mol Imaging. 2008;35(4):815–20.
89. Kato K, Schober O, Ikeda M, et al. Evaluation and comparison of 11C-choline uptake and calcification in aortic and common carotid arterial walls with combined PET/CT. Eur J Nucl Med Mol Imaging. 2009;36(10):1622–8.
90. Armani C, Catalani E, Balbarini A, Bagnoli P, Cervia D. Expression, pharmacology, and functional role of somatostatin receptor subtypes 1 and 2 in human macrophages. J Leukoc Biol. 2007;81(3):845–55.
91. Dalm VA, van Hagen PM, van Koetsveld PM, et al. Expression of somatostatin, cortistatin, and somatostatin receptors in human monocytes, macrophages, and dendritic cells. Am J Physiol Endocrinol Metab. 2003;285(2):E344–53.
92. Adams RL, Adams IP, Lindow SW, Zhong W, Atkin SL. Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Br J Cancer. 2005;92(8):1493–8.
93. Rominger A, Saam T, Vogl E, et al. In vivo imaging of macrophage activity in the coronary arteries using 68Ga-DOTATATE PET/CT: correlation with coronary calcium burden and risk factors. J Nucl Med. 2010;51(2):193–7.
94. Li X, Bauer W, Kreissl MC, et al. Specific somatostatin receptor II expression in arterial plaque: (68)Ga-DOTATATE autoradiographic, immunohistochemical and flow cytometric studies in apoE-deficient mice. Atherosclerosis. 2013;230(1):33–9.
95. Li X, Samnick S, Lapa C, et al. 68Ga-DOTATATE PET/CT for the detection of inflammation of large arteries: correlation with18F-FDG, calcium burden and risk factors. EJNMMI Res. 2012;2(1):52.
96. Schafers M, Schober O, Hermann S. Matrix-metalloproteinases as imaging targets for inflammatory activity in atherosclerotic plaques. J Nucl Med. 2010;51(5):663–6.
97. Hermann S, Starsichova A, Waschkau B, et al. Non-FDG imaging of atherosclerosis: will imaging of MMPs assess plaque vulnerability? J Nucl Cardiol. 2012;19(3):609–17.
98. Rischpler C, Nekolla SG, Beer AJ. PET/MR imaging of atherosclerosis: initial experience and outlook. Am J Nucl Med Mol Imaging. 2013;3(5):393–6.
99. Rogers WJ, Prichard JW, Hu YL, et al. Characterization of signal properties in atherosclerotic plaque components by intravascular MRI. Arterioscler Thromb Vasc Biol. 2000;20(7):1824–30.
100. Pedersen SF, Ludvigsen TP, Johannesen HH, et al. Feasibility of simultaneous PET/MR in diet-induced atherosclerotic minipig: a pilot study for translational imaging. Am J Nucl Med Mol Imaging. 2014;4(5):448–58.
101. Ripa RS, Knudsen A, Hag AM, et al. Feasibility of simultaneous PET/MR of the carotid artery: first clinical experience and comparison to PET/CT. Am J Nucl Med Mol Imaging. 2013;3(4):361–71.
102. Calcagno C, Ramachandran S, Izquierdo-Garcia D, et al. The complementary roles of dynamic contrast-enhanced MRI and 18F-fluorodeoxyglucose PET/CT for imaging of carotid atherosclerosis. Eur J Nucl Med Mol Imaging. 2013;40(12):1884–93.
103. Truijman MT, Kwee RM, van Hoof RH, et al. Combined 18F-FDG PET-CT and DCE-MRI to assess inflammation and microvascularization in atherosclerotic plaques. Stroke. 2013;44(12):3568–70.
104. Adenaw N, Salerno M. PET/MRI: current state of the art and future potential for cardiovascular applications. J Nucl Cardiol. 2013;20(6):976–89.
105. Petibon Y, El Fakhri G, Nezafat R, Johnson N, Brady T, Ouyang J. Towards coronary plaque imaging using simultaneous PET-MR: a simulation study. Phys Med Biol. 2014;59(5):1203–22.